Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 21,040 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Breast Cancer
Interventions: Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 58
States / cities: Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more

Conditions: Tendinopathy
Interventions: Amino Acids; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Breast Cancer, Lung Cancer, Colon Cancer, Solid Tumor, Adult
Interventions: PEPRR, Pep-Pal; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 64 Years
Enrollment: 538 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Electronic Cigarettes
Interventions: JUUL electronic cigarette, IQOS electronic cigarette, Own Brand cigarette; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Opioid-Related Disorders
Interventions: Placebo taken first, Generic H/A taken first, Vycavert taken first, Generic H/A plus i taken first, Generic H/A plus p taken first; Drug
Lead sponsor: Acura Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: COPD
Interventions: SpiroPD; Device
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Melanoma
Interventions: Echopulse or Echopulse HD, PolyICLC; Device · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Culturelle (Lactobacillus rhamnosus strain GG), Placebo; Dietary Supplement · Other
Lead sponsor: Northwell Health; Other
Eligibility: 5 Years to 18 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Allergic Rhinitis
Interventions: fluticasone furoate, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Head and Neck Cancer
Interventions: Ad5CMV-p53 gene, cisplatin, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 3
States / cities: Kansas City, Kansas • Lexington, Kentucky • Detroit, Michigan

Conditions: Interpersonal Violence, Homelessness
Interventions: Positive Parenting Program, Usual Care; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 16 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Post Traumatic Stress Disorder
Interventions: SMART Mobile App - Attention Bias Modification, SMART Mobile App - Attention Control Training, SMART Mobile App - Placebo Training, SMART Mobile App - Control; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Tibial Fractures
Interventions: Suprapatellar approach, Infrapatellar approach; Procedure
Lead sponsor: Florida Orthopaedic Institute; Network
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Tampa, Florida

Conditions: HIV-1-infection
Interventions: Oral fecal microbiota transplantation; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer Metastatic
Interventions: Nelitolimod; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Depression, Anxiety, Major Depressive Disorder
Interventions: CYB003, Placebo; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pancreatic Neoplasms
Interventions: Gemcitabine with escalating ascorbic acid; Drug
Lead sponsor: Joseph J. Cullen; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
Interventions: tucatinib, trastuzumab, fulvestrant; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 76
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more

Conditions: Herpes Zoster
Interventions: HZ/su vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 3,038 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Phoenix, Arizona • Elkridge, Maryland • Charlotte, North Carolina + 5 more

Conditions: Hypogonadotropic Hypogonadism, Kallmann Syndrome
Interventions: Anastrozole Pill, Testosterone, Placebo Oral Tablet; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Insulin LISPRO; Drug
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 50 Years to 95 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Overweight and Obesity
Interventions: SMART 2.0; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 35 Years
Enrollment: 638 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Autism, Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate Transdermal System; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 6 Years to 11 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Alzheimer's Disease
Interventions: Donepezil, AZD3480; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Phoenix, Arizona • Brooksville, Florida • Hallandale, Florida

Search by objective public record fields.

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Can Amino Acid Supplementation Augment the Anabolic Response in Tendon After Exercise

Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.

Assessment of Two New Electronic Cigarettes in Cigarette Smokers

Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users

Feasibility of At-Home Handheld Spirometry

FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan

Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen

S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat

Feasibility of a Positive Parenting Program for Women Experiencing Homelessness Who Have a History of Interpersonal Violence

Studying the Modification of Attention Bias Remotely After Trauma

Suprapatellar Versus Infrapatellar Nailing in Tibial Fractures: A Pilot Study

Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV

INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases

A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

A Research Trial of High Dose Vitamin C and Chemotherapy for Metastatic Pancreatic Cancer

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)

Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease

SMART 2.0: Social Mobile Approaches to Reducing weighT in Young Adults

A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)